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Abstract   
Mounting preclinical evidence has implicated the NLRP3 inflammasome in depression-related 
behaviours elicited by chronic stress  or acute lipopolysaccharide (LPS) challenge. However, 
the relevance of acute LPS as a model of depression has been questioned and behavioural 
time-courses of its effects can be inconsistent. The aims of this study were (1) to develop a 
novel protocol for repeated daily LPS administration and (2) to use this model to assess the 
involvement of NLRP3 inflammasome signalling in sustained inflammation-induced 
depressive-like behaviour in adult C57BL/6J mice deficient in NLRP3.   
Acute LPS (0.83 mg/kg; i.p.) induced sickness behaviour evident as hypolocomotor activity. 
However, there was no significant increase in depressive-like behaviour in the forced swim 
test 24 h post-administration. Interestingly, depressive-like behaviours were observed in the 
female urine sniffing test and in the sucrose preference test at 24 h, but not 48 h, post-
administration of acute LPS. To mimic a period of sustained inflammation, 3-day repeated 
increasing LPS doses (0.1, 0.42 and 0.83 mg/kg; i.p.) was compared to constant LPS doses 
(0.83 mg/kg; i.p.). Sickness behaviour was seen in response to increasing doses, but tolerance 
developed to repeated constant doses of LPS. Furthermore, 3-day increasing doses of LPS 
resulted in a significant increase in immobility time in the forced swim test, consistent with 
depressive-like behaviour. When NLRP3-/- mice received this 3-day increasing dose regimen 
of LPS, sickness behaviours were attenuated compared to wild-type mice. The behaviour in 
the forced swim test was not significantly altered in NLRP3-/- mice. 
We propose that this increasing repeated dosing LPS model of inflammation-induced 
depressive-like behaviour may better model the sustained inflammation observed in 
depression and may provide a more translationally relevant paradigm to study the 
inflammatory mechanisms that contribute to depression. 
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Highlights 
 
 A novel paradigm of sustained neuroinflammation was developed in C57BL/6 
mice 
 Repeated administration of increasing doses of lipopolysaccharide induced 
sickness and depressive behaviours but no tolerance over 3 days 
 Sickness behaviours were attenuated in NLRP3-/- mice 
 Studies in NLRP3-/- mice show this inflammasome is not required for repeated 
LPS-induced depressive behaviours 
Wickens et al.   Increasing LPS doses in mice 
 
5 
 
1. Introduction 
Neuroinflammation and the activity of cytokines have been linked with the pathology of 
depression (Dantzer et al., 2008; Raison et al., 2006). Based on several meta-analyses, 
patients with major depressive disorder exhibit elevated serum levels of pro-inflammatory 
cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1β (Dowlati et al., 
2010; Hiles et al., 2012a; Howren et al., 2009; Liu et al., 2012). This elevation of pro-
inflammatory cytokines has been shown to respond to antidepressant treatment, although the 
findings are variable. Selective serotonin reuptake inhibitors (SSRIs) have been shown to 
reduce serum levels of IL-1β and IL-6, with a concomitant resolution of depression symptoms 
(Hannestad et al., 2011; Hiles et al., 2012b). Other non-SSRI antidepressants, such as 
venlafaxine and duloxetine, do not appear to reduce cytokine levels although they can 
effectively treat depressive symptoms (Hannestad et al., 2011). This heterogeneity in response 
to antidepressant treatment indicates that inflammatory markers may be associated with 
specific subsets of depressive disorders (McNamara and Lotrich, 2012). Studies have shown 
that in major depressive disorder patients with attempted suicide, plasma levels of pro-
inflammatory cytokines are elevated (Janelidze et al., 2011). In addition, an acute inflammatory 
challenge with endotoxin (derived from E. coli) in healthy humans can result in elevated pro-
inflammatory cytokine levels and depressive symptoms (Eisenberger et al., 2010; Raison., 
2006). Treatment of hepatitis C with interferon (IFN)-α induced depression in up to a third of 
patients where antidepressant treatments can attenuate or even prevent the development of 
depressive symptoms (Musselman et al., 2001). Thus a number of lines of clinical evidence 
implicate activation of the immune system in the pathology of depression. 
 
The innate immune sensor nucleotide-binding domain, the leucine-rich repeat, and the pyrin 
domain containing protein (NLRP)3 inflammasome is a multi-protein complex that is 
responsible for the cleavage of proinflammatory cytokines, proIL-1β and proIL-18, in response 
to a range of pathogenic and endogenous danger signals (Martinon et al., 2002; Walsh et al., 
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2014). The NLRP3 inflammasome has three components: the intracellular pattern recognition 
NLRP3 receptor, the adaptor protein ASC and the effector protein caspase-1 (Tschopp, et al., 
2003). NLRP3 detection of activating stimuli results in inflammasome formation, caspase-1 
activation and IL-1β cleavage and secretion, leading to the propagation of the inflammatory 
response (Latz et al., 2013). The NLRP3 inflammasome has been reported to be involved in 
the pathology of neurological disorders that are associated with neuroinflammation, such as 
Alzheimer’s disease and depression (Heneka et al., 2014; Iwata et al., 2013). Recent studies 
have demonstrated a role of NLRP3 inflammasome signalling in the development of 
depressive-like behaviour in mice in stress- and inflammation-based models of depression 
(Zhang et al., 2014; Alcocer-Gómez et al., 2016; Li et al., 2016; Su et al., 2017; Zhu et al., 
2017). 
 
Animal models for studying the interactions between the immune system and depressive-like 
behaviours include administration of TNF-α, IFN-α or lipopolysaccharide (LPS) (Hayley et al., 
2013; Kaster et al., 2012; Lawson et al., 2013). LPS is a component of the bacterial cell wall 
which activates microglia and induces neuroinflammation (Lawson et al., 2013; Lee et al., 
2008). Acute LPS, administered systemically in mice and/or rats, induces a strong but transient 
sickness behaviour, evident as reduced locomotor activity and decreased body weight 
(Castanon et al., 2001; Kozak et al., 1994; O’Connor et al., 2009). This sickness is associated 
with elevated levels of pro-inflammatory cytokines within the brain, including TNF-α and IL-1β, 
which are thought to peak around 6 h after LPS administration, though elevated TNF-α 
expression in the brain has been reported to last up to 10 months (O’Connor et al., 2009; Qin 
et al., 2007; Quan et al., 1998). Once the overt symptoms of sickness have subsided, 
depressive-like behaviours can be assessed using behavioural paradigms such as the forced 
swim test (FST) and the sucrose preference test (SPT), typically at 24 h after acute LPS 
administration (Lawson et al., 2013; O’Connor et al., 2009). However, the time course of these 
effects varies across the literature and it is often difficult to distinguish sickness from 
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depressive-like behaviours. In mice, acute LPS-induced sickness has been reported to have 
disappeared by 24 h by some (Frenois et al., 2007; Gibb et al., 2013; Mello et al., 2013; 
O’Connor et al., 2009; Ohgi et al., 2013; Viana et al., 2010; Walker et al., 2013), and not by 
others (Biesmans et al., 2013; de Paiva et al., 2010; Godbout et al., 2005; Slalzar et al., 2012), 
whilst some even report sickness at 48 h (Corona et al., 2010; Godbout et al., 2008).  
Furthermore, the time-course of LPS-induced depressive-like behaviours is also variable, with 
some being reported as late as 72 h (Corona et al., 2013). Variation in housing (single or group 
housing) (Bogdanova et al., 2013; Karolewicz and Paul, 2001) and testing conditions (light 
cycle phase) (Huynh et al., 2011; Verma et al., 2010) may contribute to the inconsistency seen 
in the literature, although the effects of such conditions on LPS-induced behavioural changes 
has not been systematically assessed.  
 
Acute administration of LPS is routinely used to study inflammation-induced depressive-like 
behaviours in rodents, however this may not be the best model. Depression is considered a 
chronic recurrent disorder, characterized by repeated or prolonged depressive episodes and 
sustained levels of inflammatory markers (Kling et al., 2007). In order to provide a 
representative inflammation-based model with more translatability, prolonged immune system 
activation would be required. In an attempt to mimic chronic inflammation, Kubera et al (2013) 
developed a repeated, intermittent schedule for LPS administration, reporting sustained 
anhedonia in the SPT in female mice, which was reversed with fluoxetine. Other studies have 
utilised repeated administration of a constant dose of LPS in mice to induce a depressive-like 
behaviour in the FST, including 8 injections of 0.1 mg/kg LPS (Xie et al., 2012) and 10 
injections of 0.83 mg/kg LPS (Guo et al., 2014). However, repeated LPS can induce the 
development of tolerance resulting in a diminished behavioural response (Engeland et al., 
2001). 
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Mounting evidence has suggested that NLRP3 signalling could be a good target for developing 
novel antidepressants. This is largely based on preclinical studies showing that the NLRP3 
inflammasome contributes to depression-related behaviours elicited by acute LPS challenge 
or chronic stress (Zhang et al., 2014; Alcocer-Gómez et al., 2016; Li et al., 2016; Su et al., 
2017; Zhu et al., 2017). However, the involvement of NLRP3 in the behavioural changes in 
response to sustained inflammatory challenge has not been reported. The aims of this study 
were (1) to develop and characterize a novel protocol for repeated daily LPS administration 
and (2) to use this model to assess the involvement of NLRP3 inflammasome signalling in 
sustained inflammation-induced depressive-like behaviour. In developing this model we also 
attempted to replicate acute LPS-induced behavioural effects under a variety of environmental 
conditions including group versus single housing and behavioural assessment in light or dark 
phases. The involvement of NLRP3 was investigated using NLRP3-/- mice in which the entire 
coding region of the NLR family, pyrin domain containing 3 (Nlrp3) is replaced, abolishing 
expression (Kovarova et al. 2012).   
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2. Methods 
2.1. Animals 
The majority of the experiments reported here were conducted at Janssen 
Pharmaceutica facilities, accredited by the Association for the Assessment and Accreditation 
of Laboratory Animal Care, and approved by the Institutional Ethical Committee on Animal 
Experimentation, in compliance with Belgian law (Royal Decree on the protection of laboratory 
animals dd. April 6, 2010). Experiments on NLRP3-/- mice were conducted at the University of 
Bath under a Home Office project license held in accordance with the Animals (Scientific 
Procedures) Act 1986 and European Directive 2010/63/EU.  
Experiments at Janssen were performed on 10-14 week old male C57BL/6J mice 
obtained from Charles River (France). Mice were normally housed in groups of 2-4 except 
when they were singly housed as indicated in the test. Cages (L x W x H: 36 X 20 X 13 cm) 
contained wood shavings, nesting material and a plastic shelter (Mouse hutTM, Bio-Serve; L x 
W x H: 9.5 x 7.6 x 4.8 cm), with access to food and water ad libitum. Mice were under a 12 h 
light cycle, with normal lighting conditions being lights on at 06:00 h and reversed lighting 
conditions being lights on at 18:00 h, with 30 minute dim/rise phases. Mice were acclimatised 
to housing conditions, including transitioning to a reversed light cycle upon arrival, for a 
minimum of 2 weeks prior to experimentation. Temperature was maintained at 22 ± 2 °C and 
humidity at 50 ± 2 %.  
Experiments at the University of Bath were similarly performed on 10-14 week old male 
C57BL/6J or NLRP3 homozygous knockout mice on a C57BL/6J background first developed 
by Kovarova et al., (2012) (B6.129S6-Nlrp3<tm1Bhk>/J - ref:021302; Jackson Laboratory, Maine, 
US via Charles River, Margate, UK). On arrival, both NLRP3+/+ and NLRP3-/- mice were bred 
for at least one generation to establish the colony and were maintained in homozygous 
colonies. As at Janssen, mice were normally housed in groups of 3-4, in cages (L x W x H: 35 
X 20 X 15 cm) containing wood shavings, nesting material and a plastic shelf, with food and 
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water available ad libitum. Mice were under a 12-hour light cycle (lights on at 07:00 h). 
Temperature was maintained at 21 ± 1 °C and humidity at 50 – 60 %.  
All mice were handled daily for one week prior to random assignment to treatment 
groups and experimentation. For all behavioural studies mice were acclimatized to the 
behavioural room for 1 hour prior to testing. Where group or individual housing was compared, 
animals were individually housed for 2 weeks prior to treatment. Where normal lighting (lights 
on 06:00 h) was compared to reversed lighting (lights on 18:00 h) animals were maintained 
under these conditions for a minimum of 2 weeks prior to starting treatment. All behavioural 
experiments were performed between 08:00 and 17:00, under the same lighting conditions as 
the animals were housed under; so normal lighting meant that animals were tested in the light 
and reversed lighting meant that animals were tested in the dark.   
 
2.2. Treatments 
Lipopolysaccharide (LPS) from Escherichia coli (serotype 055:B5, Sigma-Aldrich) was 
prepared fresh in sterile saline (0.9 % NaCl) prior to intraperitoneal injection. All injections were 
administered at a volume of 10 ml/kg. LPS doses used were within the dose range commonly 
used in studies of depressive-like behaviour and based on previously observed acute LPS-
induced depressive-like behaviours in mice (O’Connor et al., 2009). For acute studies, mice 
were injected with 0.415 or 0.83 mg/kg LPS or saline. For repeated LPS studies, there were 
four different groups that were treated for 3 or 5 days: control (saline was injected each day); 
acute LPS (LPS was administered only on the final day); constant dose (CD) LPS (0.83 mg/kg 
LPS was injected each day) or increasing dose (ID) LPS. For ID LPS, the following doses of 
LPS were used: 0.052 / 0.104 / 0.208 / 0.415 / 0.83 mg/kg (5-day) or 0.208 / 0.415 / 0.83 mg/kg 
(3-day). Timings of injections were staggered throughout the day to enable behavioural testing 
after LPS administration at +6 h and at + 24h. Body weights were recorded daily prior to 
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injections which took place 08:00-16:00 h. Body weight is presented as % of starting weight 
prior to LPS administration. 
 
2.3. Open Field Test (OFT)  
The OFT protocol used was as described previously at Janssen (Biesmans et al., 2013) and 
the University of Bath (Almatroudi et al., 2015). At Janssen, a custom-made experimental 
apparatus consisted of 4 separate arenas (each 40 X 40 X 40 cm), allowing 4 mice to be 
tested simultaneously. An infrared camera was mounted above each arena to track the mice 
using Noldus EthoVision (version 6.1). At the University of Bath, the experimental apparatus 
consisted of a single arena (L x W x H: 41 X 41 X 38 cm) with 32 infrared photobeams (16X x 
16Y) to detect locomotion (Openfield SmartFrame, Campden Instruments). The total 
distance travelled within the arena during a 10 min low light (<10 lux) test was recorded via 
beam-breaks using Motor Monitor software (Campden Instruments). Tracking began 2 
seconds after placing the mouse in the centre of the arena and arenas were cleaned with 70 
% ethanol in between each mouse. 
 
2.4. Forced Swim Test (FST) 
The FST protocol used was as described previously at Janssen (Biesmans et al., 2013) 
and the University of Bath (Almatroudi et al., 2015). At Janssen, a custom-made experimental 
apparatus consisted of 4 separate cylinders (11 cm diameter and 10 cm deep water), which 
were automatically washed and filled with water at 24-25 ˚C between each mouse. At the 
University of Bath, the experimental apparatus consisted of a glass cylinder (44 cm h x 22 cm 
diameter), which was cleaned with 70 % ethanol, rinsed and filled with water to a depth of 30 
cm at 25 ± 1 ˚C between each test. At both locations, mice were placed in the cylinders for 6 
minutes whilst a fixed camera was used to record the mice. Immobility was manually scored, 
blind to treatment, over the 6 min test period. 
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2.5. Rotarod 
Mice were assessed in two test sessions: a ‘baseline’ test immediately prior to LPS or 
saline administration and a final test at either 6, 24 or 48 hours after treatment. Mice first 
underwent four training sessions in succession the day before treatment where mice were 
placed on the rotarod for 5 minutes each time at progressively faster speeds at 30 minute 
intervals: 16, 20 and 24 revolutions per minute (rpm), and finally an accelerating speed from 
0-40 rpm (Med Associates, model CT-ENV-575M-X5). During training, mice that had fallen off 
the rotarod were placed back on. For both the baseline test and the final test, an accelerating 
speed of 0-40 rpm in 5 minutes was used. Latency (seconds) to fall off the rotarod was 
recorded automatically via infrared cameras and mice were not replaced back onto the rotarod 
once off. 
 
2.6. Sucrose Preference Test (SPT) 
The SPT protocol used was as described previously (Biesmans et al., 2013). Animals 
were housed individually in customized Plexiglas cages (35 X 31 X 16 cm; Techniplast, Italy) 
that fitted two water bottles. Bottles were filled with either tap water (W) or 2.5 % sucrose 
dissolved in tap water (S) during the habituation phase prior to a testing phase. During the 
habituation phase, mice were housed with a pair of water bottles (W/W) or a water bottle plus 
a bottle with sucrose solution (W/S) alternating for 24-hour periods over 4 days.  The left versus 
right location of the sucrose bottle was randomised across the experimental procedure. Bottles 
were removed at the same time every morning (09:00-10:00 h) and fluid consumption was 
determined by weighing the bottles. Mice were then weighed and placed back in their cage 
with fresh pre-weighed bottles containing the appropriate solutions. The test phase was carried 
out for 2 days immediately following the administration of LPS or saline. Total consumption 
was calculated (water and sucrose consumption combined) as well as the preference for 
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sucrose (sucrose consumption as percentage of total consumption). In the event of leaking 
bottles, values were replaced by the mean of all bottles for the appropriate solution for that 
time period. This happened in less than 5 % of all bottle measurements. 
 
2.7. Female Urine Sniffing Test (FUST) 
The FUST has previously been validated using the learned helplessness (LH) model 
of depressive behaviour and the action of the antidepressant citalopram in mice (Malkesman 
et al., 2010). Prior to the experiment, female adult mice were housed in cages of 4 with grid 
floors for 2 hours to collect urine. 4 cotton-bud applicators were soaked in test tubes containing 
female urine or water for use throughout the test. Male mice were weighed and placed 
individually in a fresh cage (L x W x H: 36 X 20 X 13 cm) containing wood shavings and two 
dry cotton-bud applicators for the 30 minute habituation phase. The applicators were fixed in 
place by a custom-made device that clips onto one end of the cage and points the applicators 
down at an angle of 45 degrees and 15 cm apart, with the cotton-bud 2.5 cm above the cage 
floor. The protocol used here was adapted to incorporate one test period with two applicators 
(water and urine) as opposed to two test periods each with one applicator. For the test phase, 
the applicators and the holding device was removed and replaced with a new holding device 
with two new applicators: one soaked in water and the other soaked in female urine (left versus 
right was randomized). During the test phase, time spent sniffing each applicator, in which the 
animal was directly sniffing the bud of the applicator (biting the applicator is not counted), was 
manually scored with an observation timer for 3 minutes. Mice were then returned back to their 
home cage and the applicators placed back into the appropriate test tube for re-use. Tests 
were carried out in the light phase of the circadian cycle. Time spent sniffing female urine 
relative to water was recorded to assess anhedonic behaviour. 
 
2.8. Statistical Analysis 
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Data were analysed using one-way or two-way ANOVA. When appropriate (p < 0.05), 
Dunnett posthoc tests were applied when comparing groups to only the control, or Bonferroni 
posthoc test when comparing between multiple treatment groups. All data are represented as 
mean ± SEM. Number of mice used is indicated in each figure legend. Separate groups of 
animals were used for the data reported in each figure where typically n=10-15 mice per 
treatment group.  
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3. Results 
3.1. Effect of housing and lighting conditions on acute LPS-induced behaviours  
Acute LPS has been shown to induce sickness and depressive-like behaviour in 
C57BL/6J adult mice (O'Connor et al., 2009). However, the influence of housing arrangements 
on acute LPS-induced changes has not been established. In our first experiment, separate 
groups of mice were housed either in groups or individually and with normal lighting (lights on 
06:00 h) or reversed lighting (lights on 18:00 h) (Fig 1). A two-way ANOVA revealed a 
significant effect of treatment (F(2,133) = 284.7, p < 0.001) and housing condition (F(3,133) = 5.56, 
p < 0.01) on distance travelled in the OFT, but no interaction between the two (F(6,133) = 1.695, 
p = 0.127) (Fig 1A). A significant reduction in the total distance travelled in the OFT was seen 
6 h after acute administration of LPS, at both 0.415 and 0.83 mg/kg, in all housing conditions 
(p < 0.001) when compared to saline-treated controls. There were no significant differences 
between housing conditions in LPS-treated mice, though mice group-housed under reversed 
lighting and tested in the dark travelled further than mice group-housed under normal lighting 
and tested in the light following saline treatment (p < 0.05). On average, locomotion was 
reduced to 40 % and 32 % of control following 0.415 and 0.83 mg/kg LPS, respectively, 
consistent with a pronounced sickness behaviour 6 h following acute LPS administration. 
Depressive-like behaviour was subsequently assessed in the FST, 24 h after acute 
LPS administration (Fig 1B). A two-way ANOVA revealed a significant effect of treatment 
(F(2,131) = 3.334, p < 0.05), but no effect of housing (F(3,131) = 0.4783, p = 0.6979) and no 
interaction (F(6,131) = 1.665, p = 0.1345). Following post hoc analysis, no group showed a 
significant increase in FST immobility following LPS administration compared to saline-treated 
mice. In subsequent experiments with acute LPS all mice were group housed under normal 
lighting conditions (lights on 06:00 h) and tested in the light phase unless otherwise stated. 
 
3.2. Time course of acute LPS-induced behavioural effects 
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We investigated whether changes in sickness behaviour or depressive-like behaviours 
induced by acute LPS administration were evident at later time points (Figure 2). At 24 h post-
administration of LPS, there was a significant effect of LPS on distance travelled in the OFT 
(Fig. 2A; F(2,49) = 8.621, p < 0.001). Both 0.415 and 0.83 mg/kg LPS produced a significant 
reduction in total distance travelled in the OFT to 81% and 79% of control, respectively (p < 
0.01 and p < 0.001, respectively). There was also a significant effect of LPS on immobility in 
the FST 48 hours after injection (Fig. 2B; F(2,25) = 7.727, p < 0.01), although no group exhibited 
significantly greater immobility levels compared to control. The rotarod test was also used to 
assess motor coordination at 6, 24 and 48 h after acute LPS administration (separate groups) 
and a two-way ANOVA revealed a significant effect of treatment (F(1,54) = 13.22, p < 0.001; Fig. 
2C; Supplementary Fig 2). Bonferroni posthoc analysis revealed a reduction in performance 
compared to baseline 6 h after LPS administration (p < 0.05), but not at 24 or 48 h after 
administration. 
 
3.3. Effects of acute LPS on anhedonic behaviours 
The SPT and FUST were used as additional methods of testing depressive-like 
behaviours, in particular, anhedonic behaviour. In the SPT, a significant effect of acute LPS 
administration was observed with both total volume consumed (F(2,43) = 34.31, p < 0.001; Fig.. 
3A) and sucrose preference (F(2,43) = 4.941, p < 0.001; Fig. 3B). Both doses of LPS tested, 
0.415 and 0.83 mg/kg, produced a reduction in volume consumed to 56% and 42% of control 
and sucrose preference to 81% and 79% of control, respectively, in the first 24 h after injection 
(all Ps < 0.001). Interestingly, no significant reductions in volume consumed or sucrose 
preference were observed from 24-48 h after injection.  
The FUST was used to assess sexually motivated behaviour at 6 and 24 h (separate 
mice) after acute LPS administration (Fig. 4 A, B). In pilot studies, male mice showed a 
significant preference for sniffing at male urine over water (p < 0.05) and male mice also 
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showed a significant preference for female urine over male urine   (p < 0.001) (Supplementary 
Fig. 1). These data indicate that the preference towards female urine is partially sex-based not 
purely an olfactory stimulus. At 6 h, a 2-way ANOVA revealed a significant interaction between 
treatment and odour (F(2,17) = 11.51, p = 0.0007), with saline-injected control mice spending 
significantly more time sniffing urine when compared to water (p < 0.001), but not in mice 
treated with 0.415 or 0.83 mg/kg LPS. Furthermore, time spent sniffing urine was significantly 
reduced to 23% and 17% following 0.415 or 0.83 mg/kg LPS treatments, respectively, when 
compared to control mice (p < 0.001 for both). Similarly, there was a significant interaction 
between treatment and odour at 24 h post-administration of LPS (F(2,17) = 6.932, p = 0.0063). 
Again, saline-injected control mice spent significantly more time sniffing urine compared to 
water (p < 0.001) and this effect was also evident in both 0.415 and 0.83 mg/kg LPS treated 
groups (p < 0.001 and p < 0.05, respectively). However, at 24 h post-LPS administration, time 
spent sniffing urine was significantly reduced to 67% and 48% following 0.415 or 0.83 mg/kg 
LPS treatments, respectively, when compared to control mice (p < 0.01 and p < 0.001, 
respectively). These results demonstrate that acute LPS administration produced a significant 
effect on behaviour in both the SPT and FUST 24 h post-administration which may reflect a 
decrease in hedonic drive. 
 
3.4. Effects of repeated daily LPS administration for 3 days and 5 days 
In order to develop a protocol for assessing the effects of sustained inflammatory 
challenge on depression-related behaviours, 3-day and 5-day repeated daily dosing with LPS 
was carried out. Constant dosing (CD) of 0.83 mg/kg and increasing dosing (ID) doubling up 
to 0.83 mg/kg on final day schedules were used to identify whether tolerance to repeated 
administration of LPS developed. Sickness behaviour was assessed by locomotor behaviour 
in the OFT 6 h after the final injections and depressive-like behaviour in the FST investigated 
24 h after the final injection. In the 3-day experiment, there was a significant effect of LPS 
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treatment on body weight (Fig. 5A; F(3,52) = 160.9, p < 0.001) and distance travelled in the OFT  
(F(3,52) = 107.9, p < 0.001; Fig. 5B). Body weight at the start of the experiment was 24.5 ± 0.5 
g (n=14) for saline, 24.2 ± 0.3 g (n=14) for acute LPS, 24.6 ± 0.3 g (n=14) for CD LPS and 
24.9 ± 0.5 g (n=14) for ID LPS. At 24 h after the final injection, body weights were increased 
by 0.4% in the saline group, reduced by 8.6% for acute LPS, 12.1% for CD LPS and 11.9% for 
ID LPS (Figure 5A). A significant reduction in the distance travelled in the OFT was evident for 
all LPS-treated groups in the 3-day experiment (all p < 0.001). Taken together, the reduction 
in body weight and the reduction in locomotion are consistent with sickness behaviour following 
LPS administration. Interestingly, the CD LPS mice significantly showed less reduction in 
locomotion (61% of control) compared to that seen in either the ID LPS (38%) or acute LPS 
(37%) treated mice (p < 0.001). This observation may reflect the development of tolerance to 
CD LPS in sickness behaviour. Furthermore, after 3 days treatment, there was a significant 
effect of LPS on FST immobility (Fig. 5C; F(3,52) = 3.919, p < 0.05), with only ID LPS treatment 
causing a significant increase of 66% in immobility (p < 0.05). 
In the 5-day experiment, again there was a significant effect of LPS treatment on body 
weight (Fig. 5D; F(3,66) = 191.4, p < 0.001) and distance travelled in the OFT (Fig. 5E; F(3,66) = 
31.47, p < 0.001). Body weight at the start of the experiment was 25.1 ± 0.3 g (n=20) for saline, 
24.7 ± 0.3 g (n=19) for acute LPS, 24.7 ± 0.3 g (n=20) for CD LPS and 25.1 ± 0.4 g (n=11) for 
ID LPS. At 24 h after the final injection, body weights were increased by 1.8% in the saline 
group and reduced by 7.1% for acute LPS, 6.0% for CD LPS and 4.5% for ID LPS. A significant 
reduction in the distance travelled in the OFT was evident for all LPS-treated groups in the 5-
day experiment (all p < 0.001). The reduction in body weight and the reduction in locomotion 
indicate sickness behaviour was present during the 5-day LPS administration. However, the 
reduction in locomotion observed following acute LPS (47% of control) was significantly greater 
than the reductions seen in both CD LPS (75%; p < 0.001) and ID LPS (66%; p < 0.01). This 
finding suggests the development of tolerance to both constant and increasing doses of LPS 
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in sickness behaviour. There was no significant effect of LPS on FST immobility in the 5-day 
treatments (Fig. 5F; F(3,62) = 1.716, p = 0.1728). 
 
3.4. Effects of NLRP3 on sickness and depressive-like behaviour following acute and 3-day 
ID LPS 
The 3-day ID LPS protocol was applied to NLRP3-/- and NLRP3+/+ mice to study the influence 
of NLRP3 in the development of LPS-induced sickness and depressive-like behaviours (Fig. 
6). A significant reduction in body weight was observed in all LPS-treated groups (p < 0.001 
for all), with significantly lower body weights seen following 3-day ID LPS compared to acute 
LPS in both NLRP3+/+ and NLRP3-/- mice (p < 0.001 for both, Fig. 6A). In addition, following 3-
day ID LPS, body weight was significantly greater in NLRP3-/- mice when compared to 
NLRP3+/+ mice (p < 0.05). Furthermore, at +24 h after the final injection, a two-way ANOVA of 
body weight revealed a significant effect of treatment (F(2,138) = 658.4, p < 0.001) and genotype 
(F(1,138) = 8.716, p < 0.01), though no significant interaction between treatment and genotype 
(F(2,138) = 2.872, p = 0.06).  In the OFT at +6 h after the final injection, a two-way ANOVA 
revealed a significant effect of treatment (F(2,71) = 70.14, p < 0.001) and genotype (F(1,71) = 
33.93, p < 0.001), and a significant interaction between treatment and genotype (F(2,71) = 5.536, 
p < 0.01), on the distance travelled (Fig. 6B). Whilst a significant reduction in distance travelled 
was observed in all LPS-treated groups (p < 0.001 for all), the reduction was attenuated in 
NLRP3-/- mice following both acute LPS (p < 0.001) and 3-day ID LPS (p < 0.01) in comparison 
to NLRP3+/+ controls. As before, there was no significant difference between acute LPS and 
3-day ID LPS, indicating the avoidance of LPS tolerance. At +24 h after the final injection (Fig. 
6C), a two-way ANOVA revealed a significant effect of treatment (F(2,61) = 11.49, p < 0.001) 
and genotype (F(1,61) = 6.047, p < 0.05), and a significant interaction between treatment and 
genotype (F(2,61) = 8.113, p < 0.001), on distance travelled in the OFT. Significant reductions 
in distance travelled were observed following both acute LPS and 3-day ID LPS in NLRP3+/+ 
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mice (p < 0.001 for both), but no significant reductions in NLRP3-/- mice. In addition, following 
3-day ID LPS, the distance travelled was significantly lower in NLRP3+/+ mice when compared 
to NLRP3-/- mice (p < 0.01). These data show that 3-day LPS-induced sickness behaviour, 
evident as a body weight reduction and decreased locomotion in the OFT, is attenuated in 
NLRP3-/- mice when compared to NLRP3+/+ mice. Furthermore, the data demonstrate that 
NLRP3+/+ wildtype mice still showed sickness behaviour in the OFT +24 h after treatment 
whereas NLRP3-/- mice did not.  
A two-way ANOVA of time spent immobile in the FST at +24 h after the final LPS injection (Fig. 
6E) revealed a significant effect of treatment (F(2,71) = 11.01, p < 0.001), although there was no 
significant effect of genotype (F(2,71) = 1.822, p = 0.1813) or interaction between these factors 
(F(2,61) = 0.2544, p = 0.7761). Post hoc analysis revealed a significant increase in FST 
immobility following 3-day ID LPS in both NLRP3+/+ mice and NLRP3-/- mice (p < 0.01 and p < 
0.05, respectively). This finding indicates that 3-day ID LPS induced a depressive-like 
behaviour in the FST at +24 h after treatment in both sets of mice, independent of NLRP3 
genotype.  
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4. Discussion 
Emerging evidence suggests a role for the NLRP3 inflammasome in depression and targeting 
NLRP3 may be a useful therapeutic strategy (Iwata et al. 2013). Here we have directly tested 
the involvement of NLRP3 in depression-related behaviours using a novel model of sustained-
inflammation induced depression in wildtype and NLRP3-/- mice. In developing the model, we 
first attempted to replicate the behavioural effects of acute systemic LPS administration. We 
found that in adult C57BL/6J mice, acute LPS induced profound sickness behaviour but, at 24 
h post-LPS administration, we failed to find a significant increase in depressive-like behaviour 
in the forced swim test, regardless of environmental housing conditions. The impairment in 
locomotor activity evident at 24 h post-administration suggests that sickness behaviour 
persists and potentially confounds assessment of depressive-like behaviours at this time point. 
However, we have also assessed hedonic responses using sexually motivated behaviour in 
the FUST for the first time in acute LPS treated mice. Together with SPT, these data in the 
FUST showed a reduction in hedonic behaviour, reflecting an increase in depressive-like 
behaviour, 24 h post-administration of LPS. To examine the response to sustained 
inflammatory challenge, we have developed a repeated LPS administration paradigm, using 
daily increasing LPS doses to avoid the development of tolerance. This 3 day increasing dose 
model shows sickness behaviour at 6 h post-administration that is accompanied by a clear 
increase in immobility in the FST at 24 h. Intriguingly, this 3 day increasing dose LPS paradigm 
induced a depressive-like behaviour in NLRP3-/- mice, comparable to that seen in NLRP3+/+ 
mice, although the sickness behaviour was somewhat attenuated. Our data indicate that while 
the NLRP3 inflammasome may play a role in mediating sickness behaviour, it is not required 
for the development of depression-related behaviours following sustained activation of the 
immune system.  
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We investigated whether the absence of depressive-like behaviour following acute LPS 
administration in C57BL/6J mice was influenced by social versus individual housing or the light 
phase in which the animals were tested. It has been shown that housing and lighting conditions 
can have an effect on various behaviours, including FST immobility (Bogdanova et al., 2013; 
Dubocovich et al., 1990; Karolewicz and Paul, 2001).  In our experiments, while mice exhibited 
a slight increase in locomotion in the OFT when housed under reversed lighting conditions and 
tested in the dark, LPS-induced changes in locomotion were unaffected by group or individual 
housing and lighting conditions. A depressive-like behaviour was not observed in the FST. 
There are inconsistent reports on the effect of light phase and social conditions on FST 
immobility, with studies reporting positive, negative or no effects (Bogdanova et al., 2013; 
Huynh et al., 2011; Verma et al., 2010). For example, social isolation has been shown to both 
reduce immobility and increase immobility in the FST (Karolewicz and Paul, 2001; Ma et al., 
2011; Yates et al., 1991). Here we report for the first time a systematic assessment of these 
conditions on acute LPS-induced behavioural changes. While variations in environmental 
conditions may have subtle effects on behaviours, we failed to observe an acute LPS-induced 
depressive-like behaviour in any of the tested conditions and replication of the depressive 
effects of acute LPS in the FST could not be achieved in the present study. This finding is 
supported by other work reporting no significant LPS-induced depressive-like behaviour at 24 
h post-administration (Biesmans et al., 2013; Lawson et al., 2013). Inconsistencies in the 
behavioural effects of acute LPS and the acute inflammation associated with a single dose of 
LPS suggest acute LPS model of depressive-like behaviours in mice may not be a robust 
model of depression.  
 
One factor contributing to apparently conflicting reports in the literature is the difficulty in 
separating LPS-induced sickness and depressive-like behaviours. Exploratory behaviour is 
often used as a measure of LPS-induced sickness and we observed a reduction in OFT 
locomotion at 6 and 24 h after acute LPS administration, suggesting the presence of sickness 
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behaviour. This finding is consistent with a number of studies which report a reduction in 
distance travelled at 24 h following acute LPS treatments, all using doses between 0.33-0.83 
mg/kg (Biesmans et al., 2013; de Paiva et al., 2010; Godbout et al., 2005; Salazar et al., 2012) 
but inconsistent with others that report no effect of acute LPS on locomotion at 24 h (Frenois 
et al., 2007; Gibb et al., 2013; Mello et al., 2013; O’Connor et al., 2009; Ohgi et al., 2013; Viana 
et al., 2010; Walker et al., 2013). It has previously been reported that acute LPS caused 
reduced exploratory behaviour towards novel objects, even when the reduction in locomotion 
in the home cage was no longer seen (Haba et al., 2012). Additionally, social exploratory 
behaviour and novel object exploration have been shown to be reduced 24 h after LPS 
administration (Godbout et al., 2005; Haba et al., 2012). Assessing behaviours in the rotarod 
test 24 h after LPS injection revealed no deficits in motor co-ordination as others have 
previously shown (Custódio et al., 2013; Krzyston et al., 2008). Our data suggest that there is 
no locomotor deficit per se at 24 h, but rather that exploratory behaviour is reduced which 
could be interpreted as an indicator of depression-like behaviour.   
 
While there was little evidence in this study that acute LPS induced consistent depressive-like 
behaviour in the FST at 24 hour post-administration, we did see behavioural changes in the 
SPT and the FUST. The SPT is a common behavioural test to assess anhedonia and has been 
previously shown to be effective in LPS models of depressive-like behaviour (Park et al., 2011; 
Zhang et al., 2014). We found that acute LPS caused a reduced preference for sucrose in the 
first 24 h following injection, but not at 24-48 h. In the first 24 h there was also a reduction in 
total consumption, an indication of sickness and a potentially confounding factor (Biesmans et 
al., 2013). However, during this period, a sucrose preference is still observed, indicating the 
mice showed attenuated hedonic behaviour for some part of the test period. If sickness 
behaviour was present for the entire test period, no sucrose preference would be expected 
(Zhang et al., 2014). The FUST is a paradigm that has not previously been used to assess 
behaviours following LPS treatment. The task elicits sexually motivated hedonic behaviour that 
Wickens et al.   Increasing LPS doses in mice 
 
24 
 
has been shown to be impaired following a chronic restraint stress model of depression in 
mice, as well as respond to chronic citalopram in a learned helplessness model of depression 
(Finger et al., 2011; Malkesman et al., 2010). The FUST has also been used to evaluate the 
role of proteins such as the neurokinin-1 receptor in depressive-like behaviours in mice (Berger 
et al., 2012). In addition, a 21-day chronic stress model of depression in rats has previously 
been shown to reduce sexual behaviours in male rats (Bhattacharya and Muruganandam, 
2003). In the present study, a reduction in female urine sniffing was observed, suggesting a 
depressive effect at 24 h after LPS injection. Whilst reduced locomotion was observed in the 
OFT at 24 h after LPS injection, the finding that water sniffing is unaffected indicates that the 
reduction in urine sniffing is not a result of an overall reduction in sniffing following LPS, but an 
anhedonic response. Other studies have shown that while administration of LPS or IL-1 
induces sickness behaviour in male rats at up to 6 h, there is no change in sexual behaviour 
towards female rats, such as mounting (Avitsur et al., 1997; Yirmiya et al., 1995). Such findings 
would indicate that these sexual behaviours are not influenced by sickness. However, our 
findings show a reduced sexual motivation following acute LPS, indicating a depressive-like 
behaviour.  
 
In this study we have investigated whether repeated administration of LPS can produce a 
model of sustained inflammation-induced depressive-like behaviour. Repeated systemic 
administration of LPS is known to rapidly induce tolerance by the second administration in both 
rats and mice, whereby behavioural effects of LPS are diminished over time, even at low doses 
(Engeland et al., 2001; Franklin et al., 2003; Franklin et al., 2007). This is consistent with our 
findings when mice were administered the same LPS dose (CD) and subsequently tested in 
the OFT; the reduction in locomotion was attenuated when compared to acute LPS. Tolerance 
to LPS is a result of a refractory period in which repeated stimulation with an endotoxin results 
in an attenuated cytokine release, and therefore is an obstacle in developing a model of 
sustained inflammation (Biswas and Lopez-Collazo, 2009). However, in the 3-day increasing 
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dose group of mice, we found no difference in OFT locomotion when compared to acute LPS. 
This suggests that the mice have not developed a tolerance towards LPS regarding 
locomotion, and may therefore represent a useful model for studying the effect of sustained 
inflammation with LPS. We found that these mice exhibited a depressive-like behaviour at 24 
h after final injection. However, as no further time points have been assessed in the OFT or 
FST, it is not yet possible to confirm the absence of any confounding sickness behaviour or 
the longevity of the depressive-like behaviour observed. In the 5-day experiment increasing 
doses of LPS still resulted in the development of tolerance, as observed in the OFT. Alternative 
repeated LPS protocols have been used to induce depressive-like behaviours in mice, 8 
injections of 0.1 mg/kg LPS (Xie et al., 2012) and 10 injections of 0.83 mg/kg LPS (Guo et al., 
2014), whereby depressive-like behaviours in the FST and SPT were observed. More long-
term models include increased FST immobility following the administration of 0.25 mg/kg LPS 
twice a week for 12 weeks (Krishna et al., 2016), and anhedonia following a 4-month 
intermittent LPS administration schedule in mice, with rising and falling doses of LPS (0.75-
1.25 mg/kg) being administered over 5 days each month (Kubera et al., 2013). Such models 
may provide greater translatability by inducing inflammation over extended periods of time. 
The 3-day model presented here is the first repeated LPS model to demonstrate the avoidance 
of LPS tolerance and induce a depressive-like behaviour. However, it remains to be 
established whether the depressive-like behaviour persists in the long-term which would be 
key to the translational relevance of this new model. 
This 3-day ID LPS model was developed to enable us to investigate the involvement of the 
NLRP3 inflammasome in LPS-induced depressive-like behaviours. We found that sickness 
behaviour, as assessed by OFT locomotion and body weight reduction, was significantly 
attenuated in NLRP3-/- mice compared to NLRP3+/+ mice. However, depressive-like behaviours 
were evident in both NLRP3-/- and NLRP3+/+ suggesting that the depressive behaviours elicited 
by this 3-day ID LPS paradigm are independent of the NLRP3 inflammasome. This is 
surprising given a number of recent studies that have indicated the involvement of NLRP3 in 
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the development of depressive-like behaviour in mice in stress- and inflammation-based 
models of depression.  
LPS is recognized by the toll-like receptor 4 (TLR4) leading to activation of the NLRP3 
inflammasome in vivo. NLRP3 inflammsome signalling is characterized by its ability to activate 
pro-caspase-1 which in turn is responsible for the proteolytic cleavage of pro-IL-1 and pro-IL-
18 to generate the active form of these pro-inflammatory cytokines (Agostini et al. 2004). Thus, 
genetic deletion of caspase 1 decreases LPS-induced IL-1 secretion and this enzyme has 
been reported to be required for the development of depression-like behaviour following a 
central, but not systemic, LPS challenge (Lawson et al. 2013). Further support for this 
mechanism comes from studies where pre-treatment with the caspase 1 inhibitor Ac-YVAD-
CMK reduced the pro-depressive effects of acute LPS administration in BALB/c (0.8 mg/kg, 
ip) mice (Zhang et al. 2014) and in C57BL/6 mice (5 mg/kg ip) (Zhu et al. 2017). Furthermore, 
in vitro studies in LPS-primed macrophages and microglia showed that treatment with the 
antidepressant fluoxetine (0.1 – 10 M) inhibited NLRP3 inflammasome activation (Du et al. 
2016). These authors also showed that fluoxetine (10mg/kg/d i.p for 4 weeks) reduced the 
expression of NLRP3 and proIL-1β induced in a chronic mild stress model in mice (Du et al. 
2016). Additionally, studies in NLRP3-/- mice on a C57BL/6 background have shown that 
depression induced by chronic restraint-stress (Alcocer-Gomez et al. 2016) or chronic 
unpredictable mild stress (Su et al. 2017) depends on the presence of NLRP3. Our findings 
are the first to show a NLRP3-independent pathway mediating depression-related behaviours 
following repeated sustained LPS administration. An in vitro study has compared acute versus 
chronic LPS stimulation of peripheral mouse macrophages finding that chronic LPS stimulation 
increases IL-10 release that dampens NLRP3 inflammasome activity (Gurung et al, 2015). 
Further studies are required to understand the signalling pathways underlying this NLRP3-
independent depressive-like behaviour. We propose that chronic, repeated systemic LPS 
administration may reduce activity of the NLRP3 inflammasome pathway and shifts towards a 
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NLRP3-independent depressive behaviour that is not observed in acute LPS-induced and 
chronic stress induced models 
NLRP3 could be important in the separation of sickness and depressive-like behaviours and 
may implicate different mechanisms in the origins of these behaviours in response to acute 
and sustained models of inflammation-induced depressive-like behaviour. Sickness behaviour 
has been suggested to be an adaptive response to infection and immune system activation 
that promotes recovery by conserving energy to combat acute inflammation (Maes et al. 
2012).  While many features of sickness behaviour overlap with depression, it is not clear that 
the neurobiological mechanisms underlying these behaviours are distinct. Maes et al. (2011) 
proposed that under inflammatory conditions, the switch from sickness behaviours to 
depressive behaviours may be mediated by the activation of indoleamine 2,3-dioxygenase 
(IDO), expressed in microglia and activated by proinflammatory cytokines, which switches 
tryptophan metabolism away from the synthesis of serotonin and towards the production of 
kynurenine. Our data show that NLRP3-/- mice were provided protection from LPS-induced 
sickness, both following acute and 3 day repeated administration, but failed to attenuate the 
depressive-like behaviour in 3 day repeated administration. Furthermore, the hypolocomotion 
seen in NLRP3+/+ mice 24 h following acute LPS and 3-day ID LPS indicate the presence of 
sickness and is a confounding factor in the increased FST immobility. This confounding 
behaviour is not present in NLRP3-/- mice, indicating an absence of sickness. In a repeated 
stress model of depression, wildtype mice exhibited microglia activation and reduced food 
intake, whilst NLRP3-/- mice had reduced microglia activation and normal food consumption 
(Alcocer-Gómez et al., 2015). Locomotion 24 h after systemic acute LPS has been shown to 
not be affected by capase-1-knockout, though basal locomotion in those mice were 
significantly lower than wildtype and may therefore affect LPS-induced changes (Lawson et 
al., 2013). Our data suggest that NLRP3 does play a role in the sickness behaviour induced 
by sustained inflammatory challenge, as in the 3-day ID LPS model described here, although 
not in depressive-behaviours. One possible explanation for this distinction is that NLRP3 may 
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be able to affect immune system function independently of inflammasome activation. In T 
helper type 2 (TH2) cells NLRP3 has been shown to act as a transcription factor regulating 
TH2 differentiation (Bruchard et al. 2015).  While further biochemical studies are required to 
support this interpretation, it may be that NLRP3 is a useful marker to distinguish between 
sickness and depressive behaviours.  
 
This novel approach of using repeated increasing doses of LPS offers a potential paradigm for 
assessing the effects of sustained inflammation-induced depression-related behaviours and 
may provide a more translational model of depression than seen with acute LPS 
administration. Such models are also important in understanding the cellular mechanisms 
underlying inflammation-induced depression and defining the role of NLRP3. 
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FIGURE LEGENDS 
 
Figure 1: Effects of acute LPS administration on behaviour in C57BL/6J mice. Distance 
travelled in the open field test assessed 6 h post-administration of LPS (A) and time spent 
immobile in the forced swim test assessed 24 h post-administration of LPS (B) are shown. 
Mice were group housed (n=3/4 per cage) or singly housed throughout the experiment and 
under normal lighting (lights on 06:00h) conditions where behaviours were assessed during 
the light or under reversed lighting (lights on 18:00 h) conditions where behaviours were 
assessed during the dark phase. Values shown are mean ± SEM of n=10-15 per group. ***p 
< 0.001 LPS treatment effect compared to saline injected controls, #p < 0.05 effect of 
environmental factors. 
 
Figure 2: Time course of behavioural effects of acute LPS administration in C57BL/6J 
mice. Distance travelled in the open field test (A) 24 h post-administration of LPS and time 
spent immobile in the forced swim test (B) 48 h post-administration of LPS are shown (n=9-
18 per group, **p < 0.01, ***p < 0.001 compared to saline injected controls).  In a separate 
group of animals, motor coordination in the rotarod test (C) was examined at 6, 24 and 48 h 
post-administration of LPS (n=10 per group, #p < 0.05 compared to pre-treatment baseline 
performance). Mice were group housed (n=3/4 per cage) and behaviour assessed in the light 
cycle. All values are mean ± SEM  
 
Figure 3. Effects of acute LPS administration in the sucrose preference test in 
C57BL/6J mice. Total volume of sucrose solution (2.5%) consumed (A) and sucrose 
preference (B) are shown at 0-24 h and 24-48 h post-administration of LPS. Mice were singly 
housed throughout the experiment, lights on at 06:00 h. Values shown are mean ± SEM of 
n=15-16 per group. ***p < 0.001 compared to saline injected controls. 
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Figure 4. Effects of acute LPS administration on sexual motivation in the female urine 
sniffing test in C57BL/6J mice. Time spent sniffing either water or female urine soaked 
cotton buds at 6 h (A) and 24 h (B) post-administration of LPS is shown. Mice were group 
housed (n=3/4 per cage) and behaviour assessed in the light cycle. Values shown are mean 
± SEM of n=6-7 per group. **p < 0.01, ***p < 0.001 compared to urine sniffing saline injected 
controls) and #p < 0.05, ###p < 0.001 within group comparison vs water. 
 
Figure 5. Effects of repeated daily LPS administration on behaviour in C57BL/6J mice. 
Mice were treated for 3 days (A,B,C) or 5 days (D,E,F) with constant dose (CD) LPS (0.83 
mg/kg LPS injected each day) or increasing dose (ID) LPS (doubling concentrations each 
day to 0.83 mg/kg LPS on final day). Saline injected controls were administered injections 
daily and acute LPS (0.83 mg/kg) was administered only on the last day before testing. 
Changes in body weight (A,D), distance travelled in the open field test (B, E) and time spent 
immobile in the forced swim test (C,F) are shown. Mice were group-housed (n=3/4 per cage) 
and behaviour assessed in the light phase. Values shown are mean ± SEM of n=11-20 per 
group. **p < 0.01, ***p < 0.001 compared to saline injected controls; ##p < 0.01, ###p < 0.001 
between group comparisons as indicated. 
 
Figure 6. Effects of repeated daily LPS administration on body weight and behaviour 
in NLRP3+/+ and NLRP3-/- mice. Mice were treated for 3 days with increasing dose (ID) LPS 
(0.21 / 0.42 / 0.83 mg/kg) or acute LPS (saline / saline / 0.83 mg/kg LPS). Saline injected 
controls were administered injections daily. Changes in body weight (% of starting weight) 
were monitored (A) and at 24 h post-administration of final LPS injection (D). Distance 
travelled in the open field test at +6 h (B) and +24 h (C) was assessed. Time spent immobile 
in the forced swim test at 24 h after LPS (E) is shown. Mice were group-housed (n=3/4 per 
cage) and behaviour assessed in the light phase. Values shown are mean ± SEM of n=12-13 
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per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared to saline injected controls; #p < 0.05, 
##p < 0.01, ###p < 0.001 between group comparisons as indicated. 
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Supplementary figure 1. Pilot study demonstrating the sniffing of female urine as a 
sexually motivated behaviour rather than an olfactory stimulus.  The time male adult 
C57BL/6J mice spent sniffing cotton buds soaked in either water and male urine (A), water 
and female urine (B) or male urine and female urine (C) during a 3-minute test session is 
shown. Mice were randomly assigned to groups and exposed to two odours during the test 
session. Male mice showed a significant preference for male urine over water, and a 
significant preference for female urine over water. Panel C shows a significant preference for 
female urine over male urine, indicating a sexual preference, rather than urine as a novel 
olfactory stimulus. Values shown are mean ± SEM of n=11 per group. *p < 0.05, ***p < 
0.001. 
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Supplementary figure 2. Analysis of time spent on rotarod by adult male C57BL/6J 
mice. (See also Fig 2C in manuscript).  Six separate groups of mice (n=10 per group) were 
assessed on an accelerating rotarod test (0-40 rpm) for 5 minutes 6, 24 and 48 h after 
administration of either saline or acute lipopolysaccharide  (LPS, 0.83 mg/kg, ip). (A) Scatter 
plot of time spent on rotatrod measured as the latency to drop is expressed as the difference 
between post-treatment test time and pre-treatment baseline for each individual mouse. (B) 
The mean difference ± SEM between post-treatment testing and pre-treatment baseline for 
each treatment group is shown. Horizontal axis label applies to both A and B. Two way 
ANOVA revealed a significant effect of Treatment (F(1,54) = 4.23 P=0.044) but not of Time nor 
any significant interaction between Treatment * Time. Post-hoc pairwise comparisons (1-way 
ANOVA) revealed an almost significant effect of LPS treatment on rotatrod performance after 
6 h (p=0.07) but not after 24 h (p =0.22) or 48 h (p=0.61).In saline treated animals there 
appeared to be a small decrease in performance 48h post administration of saline which 
could be related to more time having elapsed between the training and the performance of 
the test session necessary in this experimental design.  
